MicroVention Rebrands to Terumo Neuro – Reflects Expanded Focus and Strategic Growth
MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care.
Founded in 1997 and acquired by Terumo Corporation in 2006, MicroVention has been at the forefront of developing technologies that support neurovascular surgeons in preserving and restoring brain health. As Terumo Neuro, the company is poised to continue its legacy of innovation with an enhanced focus on driving impactful growth and leveraging Terumo’s global resources and reputation.
Carsten Schroeder, President and CEO of Terumo Neuro, commented on the rebranding: "This transformation reflects our growth as a company and Terumo's confidence in our future. For eighteen years, we have maintained independent branding as MicroVention, and now, as Terumo Neuro, we’re combining the best of MicroVention with the full strength and support of the Terumo family. Our culture, speed of innovation, focus on game-changing technologies, and close collaboration with physicians will remain unchanged."
He continued, "What will evolve is a deeper partnership with Terumo, a new visual brand, and a more defined brand identity under our new name and slogan, ‘Terumo Neuro: Game-changing Impact.’ Our strategy is expanding beyond our core focus on hemorrhagic and ischemic stroke and access solutions to encompass the neurovascular patient care continuum."
As Terumo Neuro, the company will continue its close collaboration with leading physicians worldwide, translating clinical insights into technologies that enhance patient outcomes. Schroeder emphasized that the company’s DNA remains rooted in innovation for ischemic stroke, hemorrhagic stroke, and access, while expanding into broader areas of neurovascular care.
About Terumo Neuro (Formerly MicroVention, Inc.)
We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information on Terumo Neuro, please visit www.terumoneuro.com.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for one hundred years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912077658/en/
Contacts
Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+ 1 714 206 9800
christine.mccullough@microvention.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
Black Forest Labs Launches FLUX.1 Kontext, a Breakthrough in Context-aware Image Generation and Editing29.5.2025 23:27:00 EEST | Press release
Black Forest Labs, Europe’s fast-rising frontier AI research lab, announced today the release of FLUX.1 Kontext, a new suite of image generation models that introduce powerful in-context generating and editing capabilities. Kontext enables users to generate, retouch, and iteratively refine images from both text and visual inputs, without the need for finetuning or complex editing workflows. FLUX.1 Kontext is designed for creators, developers, and enterprises seeking precision and creative control. The model can understand and extract visual concepts from images, maintain stylistic and character consistency across multiple scenes, and apply localized edits with exceptional fidelity. This enables seamless visual storytelling, fast ideation, and highly targeted content generation, all at inference speeds up to 8x faster than leading alternatives. "FLUX.1 Kontext represents a fundamental shift from traditional editing approaches by unifying image generation and editing in a single flow mat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom